JNJ · Earnings call · 2026Q3T · Full report
Strategic Initiatives
JOHNSON & JOHNSON · 2026-10-13 · Importance 31 · Surprise 42 · In source text
Management is concentrating strategic investment on oncology, immunology, neuroscience, cardiovascular, surgery, and vision to support durable growth and a path to double-digit growth by the end of the decade. In MedTech, the company is prioritizing corrective actions for Abiomed, commercialization of OTTAVA, and improvement in cardiovascular and surgery performance outside the United States rather than assuming additional MedTech acquisitions. Management will present the earlier-stage pipeline, 2027 outlook, and strategic growth drivers at the December 8 Enterprise Business Review.
Key facts
- JNJ-4.8 (guselkumab + golimumab) is now in Phase 3 after compelling Phase 2 data for refractory patients.
- Johnson & Johnson said the potential from their cardiovascular launches, including next-generation PFA and IVL catheters, additional data supporting Impella, and OTTAVA in robotic surgery are not yet fully reflected in their growth.
- Johnson & Johnson said they will provide more details about their portfolio and later-stage pipeline at their Enterprise Business Review in December.
- Joe stated that the statement about double-digit growth by the end of the decade refers to internal strategic investments, not assumed inorganic additions.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | JNJ-4.8 (guselkumab + golimumab) is now in Phase 3 after compelling Phase 2 data for refractory patients. |
| revenue | positive | contingent | — | JNJ-4.8 (guselkumab + golimumab) is now in Phase 3 after compelling Phase 2 data for refractory patients. |